Patents by Inventor Benjamin Levine Ebert

Benjamin Levine Ebert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of identifying and treating a person having a predisposition to or afflicted with a cardiometabolic disease
    Patent number: 11788144
    Abstract: The invention relates to method for identifying and selecting a subject with increased risk of developing a cardiometabolic disease and optionally, providing a personalized medicine method, which may involve sequencing at least part of a genome of one or more cells in a blood sample of the subject and identifying from the sequencing one or more mutations in one or more somatic mutations.
    Type: Grant
    Filed: August 16, 2021
    Date of Patent: October 17, 2023
    Assignees: The Brigham and Women's Hospital, Inc., The General Hospital Corporation
    Inventors: Benjamin Levine Ebert, Siddhartha Jaiswal, Sekar Kathiresan
  • Disease biomarkers and treatment methods related thereto
    Patent number: 11785925
    Abstract: The present invention features a knock-in mouse comprising a mutation in an endogenous CRBN locus and methods of use thereof.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: October 17, 2023
    Assignees: THE BROAD INSTITUTE, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Benjamin Levine Ebert, Jan Krönke, Steven A. Carr, Namrata D. Udeshi, Emma Fink
  • Methods of characterizing resistance to modulators of Cereblon
    Patent number: 11459613
    Abstract: In one aspect, the present invention features method of identifying a cell resistant to a modulator of Cereblon (CRBN). In another aspect, the present invention features a method of characterizing sensitivity of a subject to a modulator of CRBN. In yet another aspect, the present invention features a method of monitoring sensitivity of a subject to a modulator of CRBN.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: October 4, 2022
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Benjamin Levine Ebert, Quinlan Sievers
  • METHODS OF CHARACTERIZING RESISTANCE TO MODULATORS OF CEREBLON
    Publication number: 20220251651
    Abstract: In one aspect, the present invention features method of identifying a cell resistant to a modulator of Cereblon (CRBN). In another aspect, the present invention features a method of characterizing sensitivity of a subject to a modulator of CRBN. In yet another aspect, the present invention features a method of monitoring sensitivity of a subject to a modulator of CRBN.
    Type: Application
    Filed: September 9, 2016
    Publication date: August 11, 2022
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: BENJAMIN LEVINE EBERT, QUINLAN SIEVERS
  • METHODS OF IDENTIFYING AND TREATING A PERSON HAVING A PREDISPOSITION TO OR AFFLICTED WITH A CARDIOMETABOLIC DISEASE
    Publication number: 20220170100
    Abstract: The invention relates to method for identifying and selecting a subject with increased risk of developing a cardiometabolic disease and optionally, providing a personalized medicine method, which may involve sequencing at least part of a genome of one or more cells in a blood sample of the subject and identifying from said sequencing one or more mutations in one or more somatic mutations.
    Type: Application
    Filed: August 16, 2021
    Publication date: June 2, 2022
    Inventors: Benjamin Levine Ebert, Siddhartha Jaiswal, Sekar Kathiresan
  • METHODS OF IDENTIFYING DRUG-MODULATED POLYPEPTIDE TARGETS FOR DEGRADATION
    Publication number: 20220017938
    Abstract: In one aspect, the invention features a method for identifying a drug-modulated polypeptide substrate of cereblon (CRBN). In another aspect, the invention features a method of identifying a polypeptide target of a modulator of CRBN. In yet another aspect, the invention provides methods of monitoring or characterizing the sensitivity of a subject to a modulator of CRBN.
    Type: Application
    Filed: October 7, 2021
    Publication date: January 20, 2022
    Applicants: THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: TARJEI MIKKELSEN, BENJAMIN LEVINE EBERT, QUINLAN SIEVERS
  • Methods of identifying a polypeptide target for degradation by a modulator of CRBN
    Patent number: 11168345
    Abstract: In one aspect, the invention features a method for identifying a drug-modulated polypeptide substrate of cereblon (CRBN). In another aspect, the invention features a method of identifying a polypeptide target of a modulator of CRBN. In yet another aspect, the invention provides methods of monitoring or characterizing the sensitivity of a subject to a modulator of CRBN.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: November 9, 2021
    Assignees: THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Tarjei Mikkelsen, Benjamin Levine Ebert, Quinlan Sievers
  • Mutation signatures for predicting the survivability of myelodysplastic syndrome subjects
    Patent number: 10711308
    Abstract: Somatic non-silent mutations on selected biomarkers are reliable indicators for the overall survival of Myelodysplastic Syndrome subjects.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: July 14, 2020
    Assignees: BRIGHAM AND WOMEN'S HOSPITAL, INC., DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Rafael Bejar, Benjamin Levine Ebert, Kristen Stevenson, Donna Neuberg
  • KNOCK-IN RODENT COMPRISING A MUTATION IN AN ENDOGENOUS CRBN LOCUS AND METHODS OF USE THEREOF
    Publication number: 20190274292
    Abstract: The present invention features a knock-in mouse comprising a mutation in an endogenous CRBN locus and methods of use thereof.
    Type: Application
    Filed: May 10, 2019
    Publication date: September 12, 2019
    Applicants: THE BROAD INSTITUTE, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: BENJAMIN LEVINE EBERT, JAN KRÖNKE, STEVEN A. CARR, NAMRATA D. UDESHI, EMMA FINK
  • IMiD screening methods IMiD-sensitive cells with mutant CRBN
    Patent number: 10334829
    Abstract: The present invention features a knock-in mouse comprising a mutation in an endogenous CRBN locus and methods of use thereof.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: July 2, 2019
    Assignees: The Broad Institute, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Benjamin Levine Ebert, Jan Krönke, Steven A. Carr, Namrata D. Udeshi, Emma Fink
  • Oncogenic Models Based on Delivery and Use of the CRISPR-Cas Systems, Vectors and Compositions
    Publication number: 20190106710
    Abstract: The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are delivery systems and tissues or organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells to enable genome engineering in an organism to recapitulate the genetic complexity of disease or a condition and further interrogate gene function.
    Type: Application
    Filed: June 7, 2018
    Publication date: April 11, 2019
    Applicants: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Feng Zhang, Benjamin Levine Ebert, Dirk Heckl
  • METHODS OF IDENTIFYING DRUG-MODULATED POLYPEPTIDE TARGETS FOR DEGRADATION
    Publication number: 20190071731
    Abstract: In one aspect, the invention features a method for identifying a drug-modulated polypeptide substrate of cereblon (CRBN). In another aspect, the invention features a method of identifying a polypeptide target of a modulator of CRBN. In yet another aspect, the invention provides methods of monitoring or characterizing the sensitivity of a subject to a modulator of CRBN.
    Type: Application
    Filed: September 9, 2016
    Publication date: March 7, 2019
    Applicants: THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: TARJEI MIKKELSEN, BENJAMIN LEVINE EBERT, QUINLAN SIEVERS
  • KNOCK-IN RODENT COMPRISING A MUTATION IN AN ENDOGENOUS CRBN LOCUS AND METHODS OF USE THEREOF
    Publication number: 20180343839
    Abstract: The present invention features a knock-in mouse comprising a mutation in an endogenous CRBN locus and methods of use thereof.
    Type: Application
    Filed: April 17, 2018
    Publication date: December 6, 2018
    Applicants: THE BROAD INSTITUTE, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: BENJAMIN LEVINE EBERT, JAN KRÖNKE, STEVEN A. CARR, NAMRATA D. UDESHI, EMMA FINK
  • Knock-in rodent comprising a mutation in an endogenous CRBN locus and methods of use thereof
    Patent number: 9974289
    Abstract: The present invention features a knock-in mouse comprising a mutation in an endogenous CRBN locus and methods of use thereof.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: May 22, 2018
    Assignees: The Broad Institute, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Benjamin Levine Ebert, Jan Krönke, Steven A. Carr, Namrata D. Udeshi, Emma Fink
  • METHOD OF IDENTIFYING AND TREATING A PERSON HAVING A PREDISPOSITION TO OR AFFLICTED WITH A CARDIOMETABOLIC DISEASE
    Publication number: 20180010185
    Abstract: The invention relates to method for identifying and selecting a subject with increased risk of developing a cardiometabolic disease and optionally, providing a personalized medicine method, which may involve sequencing at least part of a genome of one or more cells in a blood sample of the subject and identifying from said sequencing one or more mutations in one or more somatic mutations.
    Type: Application
    Filed: November 25, 2015
    Publication date: January 11, 2018
    Inventors: Benjamin Levine Ebert, Siddhartha Jaiswal, Sekar Kathiresan
  • KNOCK-IN RODENT COMPRISING A MUTATION IN AN ENDOGENOUS CRBN LOCUS AND METHODS OF USE THEREOF
    Publication number: 20160338326
    Abstract: The present invention features a knock-in mouse comprising a mutation in an endogenous CRBN locus and methods of use thereof.
    Type: Application
    Filed: March 18, 2016
    Publication date: November 24, 2016
    Applicants: THE BROAD INSTITUTE, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: BENJAMIN LEVINE EBERT, JAN KRÖNKE, STEVEN A. CARR, NAMRATA D. UDESHI, EMMA FINK
  • COMPOSITIONS AND METHODS FOR SELECTING A TREATMENT FOR B-CELL NEOPLASIAS
    Publication number: 20160282354
    Abstract: The present invention features compositions and methods for identifying a subject having a B cell neoplasia or related condition responsive to treatment with lenalidomide and lenalidoinide-related compounds.
    Type: Application
    Filed: November 7, 2014
    Publication date: September 29, 2016
    Applicants: THE BROAD INSTITUTE, INC., THE BRIGHAM & WOMEN'S HOSPITAL, INC.
    Inventors: BENJAMIN LEVINE EBERT, STEVEN A. CARR, JAN KRÖNKE, NAMRATA D. UDESHI, EMMA FINK
  • ONCOGENIC MODELS BASED ON DELIVERY AND USE OF THE CRISPR-CAS SYSTEMS, VECTORS AND COMPOSITIONS
    Publication number: 20160168594
    Abstract: The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are delivery systems and tissues or organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells to enable genome engineering in an organism to recapitulate the genetic complexity of disease or a condition and further interrogate gene function.
    Type: Application
    Filed: December 16, 2015
    Publication date: June 16, 2016
    Inventors: Feng Zhang, Benjamin Levine Ebert, Dirk Heckl
  • Mutation Signatures for Predicting the Survivability of Myelodysplastic Syndrome Subjects
    Publication number: 20140127690
    Abstract: Somatic non-silent mutations on selected biomarkers are reliable indicators for the overall survival of Myelodysplastic Syndrome subjects.
    Type: Application
    Filed: June 15, 2012
    Publication date: May 8, 2014
    Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Rafael Bejar, Benjamin Levine Ebert, Kristen Stevenson, Donna Neuberg
  • LSC AND HSC SIGNATURES FOR PREDICTING SURVIVAL OF PATIENTS HAVING HEMATOLOGICAL CANCER
    Publication number: 20120237488
    Abstract: A method for determining prognosis in a subject having a hematological cancer comprising: a) determining an expression profile by measuring the gene expression levels of a set of genes selected from a leukemic stem cell (LSC) gene signature marker set or an hematopoietic stem cell (HSC) gene signature marker set, in a sample from a subject; and b) classifying the subject as having a good prognosis or a poor prognosis based on the expression profile; wherein a good prognosis predicts an increased likelihood of survival within a predetermined period after initial diagnosis and poor prognosis predicts a decreased likelihood of survival within the predetermined period after initial diagnosis.
    Type: Application
    Filed: December 3, 2010
    Publication date: September 20, 2012
    Applicants: UNIVERSITY HEALTH NETWORK, THE BRIGHAM AND WOMEN'S HOSPITAL, INC., THE HOSPITAL FOR SICK CHILDREN
    Inventors: John Dick, Kolja Eppert, Igor Jurisica, Levi David Waldron, Mark Minden, Eric Lechman, Bjorn Nilsson, Benjamin Levine Ebert, Katsuto Takenaka, Jayne S. Danska